Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Paratek Pharmaceuticals Inc    PRTK

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
04/24/2017 04/25/2017 04/26/2017 04/27/2017 04/28/2017 Date
21.4(c) 21.75(c) 22(c) 21.65(c) 21.45(c) Last
947 958 711 619 550 079 444 656 567 047 Volume
-2.73% +1.64% +1.15% -1.59% -0.92% Change
More quotes
Financials ($)
Sales 2017 5,45 M
EBIT 2017 -107 M
Net income 2017 -110 M
Finance 2017 18,5 M
Yield 2017 -
Sales 2018 26,5 M
EBIT 2018 -83,2 M
Net income 2018 -85,6 M
Debt 2018 7,06 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 103x
EV / Sales2018 22,3x
Capitalization 582 M
More Financials
Company
Paratek Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry.Its products include Omadacycline and Sarecycline.The company was founded in February 2001 and is... 
More about the company
Surperformance© ratings of Paratek Pharmaceuticals In
Trading Rating : Investor Rating :
More Ratings
Latest news on PARATEK PHARMACEUTICALS IN
04/28 PARATEK PHARMACEUTICALS : Zeroes in on New Antibiotic While Big Pharma Carefully..
04/26 Paratek Pharmaceuticals to Report First Quarter 2017 Financial Results and Pr..
04/26 PARATEK PHARMACEUTICALS : Omadacycline Concentrations Exceed Tigecycline Levels ..
04/25 PARATEK PHARMACEUTICALS : and Zai Lab Announce Collaboration, Development and Li..
04/25 PARATEK PHARMACEUTICALS : New Microbiology Data from Paratek Pharmaceuticals Sho..
04/25 PARATEK PHARMACEUTICALS : New Health Economics Studies Highlight the Potential f..
04/25 Omadacycline Concentrations Exceed Tigecycline Levels in Lungs and Epithelial..
04/24 PARATEK PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Regu..
04/24 PARATEK PHARMACEUTICALS : to Present New Data from Omadacycline Development Prog..
04/24 New Health Economics Studies Highlight the Potential for Paratek Pharmaceutic..
More news
Sector news : Bio Therapeutic Drugs
04/28 REGENERON PHARMACEUTICALS : Sanofi beats profit forecasts, upbeat on prospects f..
04/28DJSanofi 1st-Quarter Net Profit Rises on Sale of Animal-Health Unit
04/27 AMGEN : Cost controls help offset lower Amgen first-quarter drug sales
04/26 New GlaxoSmithKline CEO wants fewer, bigger new drug launches
04/18 Johnson & Johnson first quarter revenue misses estimates; new forecast includ..
More sector news : Bio Therapeutic Drugs
Latest Tweets
02:54pParatek Pharmaceuticals Inc $PRTK Scheduled to Post Quarterly Earnings on Mon.. 
04/27Paratek Pharmaceuticals Inc $PRTK Downgraded by Zacks Investment Research  
04/26The Antimicrobial Resistance Crisis
1
04/25Paratek's IV omadacycline effective in penetrating lung tissue and epithelial..
1
04/24Paratek Pharmaceuticals's buy rating reiterated at Cantor Fitzgerald. $32.00 .. 
More tweets
Qtime:14
News from SeekingAlpha
04/26 The Antimicrobial Resistance Crisis
04/25 Paratek's IV omadacycline effective in penetrating lung tissue and epithelial..
04/12 MOTIF BIO : Way Too Risky
04/10 PARATEK PHARMACEUTICALS : A Significantly Derisked Core Buy In Biotech
04/09 PRO WEEKLY DIGEST : Value Plus A Catalyst Investing With Seneca Park Research
Advertisement
Chart PARATEK PHARMACEUTICALS IN
Duration : Period :
Paratek Pharmaceuticals In Technical Analysis Chart | PRTK | US6993743029 | 4-Traders
Full-screen chart
Technical analysis trends PARATEK PHARMACEU...
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Average target price 41,3 $
Spread / Average Target 92%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Michael F. Bigham Chairman & Chief Executive Officer
Evan Loh President, COO, Director & CMO
Douglas W. Pagán CFO & Principal Accounting Officer
Thomas John Dietz Independent Director
Richard J. Lim Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
PARATEK PHARMACEUTICAL..39.29%582
AMGEN, INC.11.70%120 105
CELGENE CORPORATION7.17%96 861
GILEAD SCIENCES, INC.-4.27%89 611
REGENERON PHARMACEUTIC..5.83%41 293
VERTEX PHARMACEUTICALS..60.58%29 390
More Results